Pathogenic variants in titin predispose to anthracycline cardiotoxicity: insights from an hiPSC-CM model

30 August 2025 (12:30 - 12:40)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Hanne Boen

University Hospital Antwerp, Edegem (Belgium)

5 More presentations in this session

Presentation thumbnail

Use of direct oral anticoagulants in patients with atrial fibrillation and cancer: a subanalysis of the nationwide Italian START registry

Doctor V. Cormaci (Rome, IT)

Abstract Slides Video

Presentation thumbnail

Atorvastatin and left ventricular global longitudinal strain during anthracycline-based chemotherapy

Doctor V. Juhasz (Boston, US)

Abstract Slides Video

Presentation thumbnail

Impact of anemia on clinical outcomes of active cancer patients with low-risk pulmonary embolism receiving rivaroxaban: insight from the ONCO PE trial

Doctor R. Chatani (Kurashiki, JP)

Abstract Slides Video

Presentation thumbnail

Cardiovascular adverse events in primary lung cancer patients treated with immune checkpoint inhibitors: a nationwide database study

Doctor T. Isawa (Sendai, JP)

Abstract Slides Video

Presentation thumbnail

Improved risk stratification with SCORE2 on top of HFA-ICOS in cancer patients without previous cardiovascular disease

Mrs M. Gynnild (Trondheim, NO)

Abstract Slides Video

Access the full session

Session thumbnail

Anticipating risk to protect the heart during cancer treatment

The Event

Event poster

ESC Congress 2025

30 August 2025 12:30 CET

You may be interested in

Congress Presentation

Bridging the cardio-oncology gap with insights from a functional TTN-truncating variant model

Congress Presentation

Future directions

Congress Session

New treatment targets for personalised therapy in genetic cardiomyopathies

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources